Suven Life Sciences Company Description

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally.

The company engages in drug discovery and development of new chemical entities in central nervous system diseases.

Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders.

The company is developing Usmarapride (SUVN-D4010), a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders.

The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003.

The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.

Suven Life Sciences Limited

Country	India
Founded	1989
Industry	Medicinal Chemicals and Botanical Products
Employees	141
CEO	Venkateswarlu Jasti

Contact Details

Address: 8-2-334, SDE Serene Chambers Hyderabad, 500034 India
Phone	91 40 2354 1142
Website	suven.com

Stock Details

Ticker Symbol	530239
Exchange	Bombay Stock Exchange
Fiscal Year	April - March
Reporting Currency	INR
SIC Code	2833

Key Executives

Name	Position
Venkateswarlu Jasti	Chief Executive Officer
M. Kumar	Chief Financial Officer